{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-089578","form_type":"8-K","ticker":"BRNS","cik":"0001828185","company_name":"Barinthus Biotherapeutics plc.","filed_at":"2023-08-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.531421+00:00","generated_at":"2026-06-11T18:59:30.346675+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Vaccitech Q2 net loss $23.8M ($0.62 per share); cash $173M extends runway into Q2 2025","bullets":["Net loss $23.8M, widened from $18.2M in Q1 2023; revenue $0.3M from AstraZeneca royalties.","R&D expense $13.5M, up from $9.8M Q1, driven by HBV and SNAPvax IND-enabling studies.","Cash $173M vs $191.3M at Q1; operating cash burn $17M; expects runway into Q2 2025.","Final HBV002 data presented at EASL; VTP-300 induced HBsAg reductions; interim Phase 2 data expected H2 2023.","CMO Dr. Margaret Marshall retired July 2023; will remain as consultant."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-089578","json":"https://secwatch.observer/filing/0001104659-23-089578.json","markdown":"https://secwatch.observer/filing/0001104659-23-089578.md","text":"https://secwatch.observer/filing/0001104659-23-089578.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1828185/000110465923089578/0001104659-23-089578-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1828185/000110465923089578/tm2323324d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T18:59:30.346675+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a99ca40a8e03922686f48d9fa4c636a2e47ba287","claim":"Barinthus Biotherapeutics plc. reported second quarter of 2023 results: revenue $0.3 million.","evidence_excerpt":"plans, we expect our cash runway to fund our operating expenses and capital expenditure requirements into the second quarter of 2025. 2 · Revenue: Revenue consisted of $0.3 million in the second quarter of 2023 compared to $0.5 million in the first quarter of 2023. Revenue was comprised of the Company’s share of royalties received by Oxford University","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1828185/000110465923089578/0001104659-23-089578-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter of 2023"},{"label":"Revenue","value":"$0.3 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}